The Pulmonary Vasculitides

Clinics in Chest Medicine

Volumn 31, Issue 3, 2010, Pages 519-536

  Frankel, Stephen K ^a,b   Jayne, David ^c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Churg Strauss vasculitis; Microscopic polyangitiis; Pulmonary vasculitides; Wegener granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; AORTA ARCH SYNDROME; BRONCHOSCOPY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EXTRACORPOREAL OXYGENATION; GIANT CELL ARTERITIS; GOODPASTURE SYNDROME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INCIDENCE; KIDNEY FUNCTION TEST; LEUKOPENIA; LOW DRUG DOSE; LUNG HEMORRHAGE; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NERVE CONDUCTION; OBSTRUCTIVE AIRWAY DISEASE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PREVALENCE; PRIORITY JOURNAL; PULMONARY VASCULITIS; REVIEW; SMALL VESSEL VASCULITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 77955405465     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.04.005     Document Type: Review

References (111)

1. Gatenby P.A., Lucas R.M., Engelsen O., et al. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?. Arthritis Rheum 2009, 61:1417.
2. Watts R.A., Scott D.G., Jayne D.R., et al. Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype?. Nephrol Dial Transplant 2008, 23:3928.
3. Cotch M.F., Hoffman G.S., Yerg D.E., et al. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population based data sources. Arthritis Rheum 1996, 39:87.
4. Reinhold-Keller E., Herlyn K., Wagner-Bastmeyer R., et al. Stable incidence of primary systemic vasculitides over five years: results from the German Vasculitis Register. Arthritis Rheum 2005, 53:93.
5. Watts R.A., Lane S.E., Bentham G., et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000, 43:414.
6. Leavitt R.Y., Fauci A.S., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990, 33:1101.
7. Lightfoot R.W., Michel B.A., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990, 33:1088.
8. Masi A.T., Hunder G.G., Lie J.T., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33:1094.
9. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187.
10. Rao J.K., Allen N.B., Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998, 129:345.
11. Hagen E.C., Daha M.R., Hermans J., et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998, 53:743.
12. Savige J., Gillis D., Benson E., et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999, 111:507.
13. Mandl L.A., Solomon D.H., Smith E.L., et al. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis. Arch Intern Med 2002, 162:1509.
14. Zamora M.R., Warner M.L., Tuder R., et al. Diffuse alveolar hemorrhage and systemic lupus erthematosus (SLE): clinical presentation, histology, survival and outcome. Medicine 1997, 76:192.
15. Vanoli M., Castellani M., Bacchiani G., et al. Non-invasive assessment of pulmonary artery involvement in Takayasu's arteritis. Clin Exp Rheumatol 1999, 17:215.
16. Yamada I., Shibuya H., Matsubara O., et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. Am J Roentgenol 1992, 159:263.
17. Erkan F., Gul A., Tasali E. Pulmonary manifestations of Behcet's disease. Thorax 2001, 56:572.
18. Anderson G., Coles E.T., Crane M., et al. Wegener's granulomatosis: a series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992, 83:427.
19. Fauci A.S., Haynes B.F., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76.
20. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488.
21. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 2000, 43:1021.
22. Romas E., Murphy B.F., d'Apice A.J., et al. Wegener's granulomatosis: clinical features and prognosis in 37 patients. Aust N Z J Med 1993, 23:168.
23. Cordier J.-F., Valeyre D., Guillevin L., et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990, 97:906.
24. Reuter M., Schnabel A., Wesner F., et al. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest 1998, 114:500.
25. Lie J.T. Illustrated histopathologic classification criteria for selected vasculitic syndromes. Arthritis Rheum 1990, 33:1074.
26. Travis W.D., Hoffman G.S., Leavitt R.Y., et al. Surgical pathology of the lung in Wegener's granulomatosis. Am J Surg Pathol 1991, 15:315.
27. Gayraud M., Guillevin L., le Toumelin P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666.
28. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421.
29. Guillevin L., Lhote F., Gherardi R. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: clinical aspects, neurologic manifestations, and treatment. Neurol Clin 1997, 15:865.
30. Lhote F., Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Semin Respir Crit Care Med 1998, 19:27.
31. Lhote F., Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 1995, 21:911.
32. Lauque D., Cadranel J., Lazor R., et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies " Orphelines" Pulmonaires (GERM" O" P). Medicine (Baltimore) 2000, 79:222.
33. Lanham J., Elkon K., Pusey C., et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984, 63:65.
34. Sinico R.A., Di Toma L., Maggiore U., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926.
35. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine 1999, 78:26.
36. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996, 75:17.
37. Solans R., Bosch J.A., Perez-Bocanegra C., et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001, 40:763.
38. Sehgal M., Swanson J.W., DeRemee R.A., et al. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc 1995, 70:337.
39. Fong C., Schmidt G., Cain N., et al. Churg-Strauss syndrome, cardiac involvement and life threatening ventricular arrhythmias. Aust N Z J Med 1992, 22:167.
40. Morgan J.M., Raposo L., Gibson D.G. Cardiac involvement in Churg-Strauss syndrome shown by echocardiography. Br Heart J 1989, 62:462.
41. Pagnoux C., Guillevin L. Cardiac involvement in small and medium-sized vessel vasculitides. Lupus 2005, 14:718.
42. Smedema J.P., van Paassen P., van Kroonenburgh M.J., et al. Cardiac involvement of Churg Strauss syndrome demonstrated by magnetic resonance imaging. Clin Exp Rheumatol 2004, 22:S75.
43. Val-Bernal J.F., Mayorga M., Garcia-Alberdi E., et al. Churg-Strauss syndrome and sudden cardiac death. Cardiovasc Pathol 2003, 12:94.
44. Buschman D.L., Waldron J.A., King T.E. Churg Strauss pulmonary vasculitis: high resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990, 142:458.
45. Choi Y.H., Im J.-G., Han B.K., et al. Thoracic manifestations of Churg-Strauss syndrome. Chest 2000, 117:117.
46. Staples C.A. Pulmonary angiitis and granulomatosis. Radiol Clin North Am 1991, 29:973.
47. Worthy S.A., Muller N.L., Hansell D.M., et al. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol 1998, 170:297.
48. Schnabel A., Csernok E., Braun J., et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999, 54:771.
49. Wallaert B., Gosset P., Prin L., et al. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur Respir J 1993, 6:413.
50. Le Gall C., Pham S., Vignes S., et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J 2000, 15:978.
51. Weschler M.E., Finn D., Gunawardena D., et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000, 117:708.
52. Weschler M.E., Garpestad E., Flier S.R., et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998, 279:455.
53. Coulter D. Pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000, 9:273.
54. Jamaleddine G., Diab K., Tabbarah Z., et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002, 31:218.
55. Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003, 115:284.
56. Lilly C.M., Churg A., Lazarovich M., et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol 2002, 109:S1.
57. Weller P.F., Plaut M., Taggart V., et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001, 108:175.
58. Wechsler M.E., Wong D.A., Miller M.K., et al. Churg-Strauss syndrome in patients treated with omalizumab. Chest 2009, 136:507.
59. Holsinger D.R., Osmundson P.J., Edwards J.E. The heart in periarteritis nodosa. Circulation 1962, 25:610.
60. Schrader M.L., Hochman J.S., Bulkley B.H. The heart in polyarteritis nodosa: a clinicopathologic study. Am Heart J 1985, 109:1353.
61. Frankel S.K., Schwarz M.I. Cardiopulmonary manifestations of vasculitis. Vasculitis 2008, 149-160. Oxford University Press, Oxford (UK). 2nd edition. G.V. Ball, S.L. Bridges (Eds.).
62. Lie J.T. Isolated pulmonary Takayasu arteritis: clinicopathologic characteristics. Mod Pathol 1996, 9:469.
63. Lie J.T. Pathology of isolated nonclassical and catastrophic manifestations of Takayasu arteritis. Int J Cardiol 1998, 66:S11.
64. Yamada I., Numano F., Suzuki S. Takayasu's arteritis: evaluation with MR imaging. Radiology 1993, 188:89.
65. Van der Woude F.J., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 1:425.
66. Cohen-Tervaert J.W., van der Woude F.J., Fauci A.S., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989, 149:2461.
67. Gross W.L. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995, 21:987.
68. Nolle B., Specks U., Ludemann J., et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989, 111:28.
69. Cohen P., Guillevin L., Baril L., et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol 1995, 13:193.
70. Schonermarck U., Lamprecht P., Csernok E., et al. Prevalence and spectrum of rheumatic diseases associated with proteinase-3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) 2001, 40:178.
71. Ara J., Mirapeix E., Rodriguez R., et al. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999, 14:1667.
72. Choi H.K., Liu S., Merkel P.A., et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on myeloperoxidase antibodies. J Rheumatol 2001, 28:1584.
73. Cohen Tervaert J.W., Goldschmeding R., Elema J.D., et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990, 33:1264.
74. Cohen-Tervaert J.W., Goldschmeding R., Elema J.D., et al. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome. Thorax 1991, 46:70.
75. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025.
76. Jayne D.R., Gaskin G., Pusey C.D., et al. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995, 88:127.
77. Kerr G.S., Fleisher T.A., Hallahan C.W., et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. Adv Exp Med Biol 1993, 336:411.
78. Segelmark M., Phillips B.D., Hogan S.L., et al. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol 2003, 10:769.
79. Sanders J.S., Huitma M.G., Kallenberg C.G., et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006, 45:724.
80. Summers R.M., Aggarwal N.R., Sneller M.C., et al. CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis. Chest 2002, 121:242.
81. Schnabel A., Holl-Ulrich K., Dalhoff K., et al. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 1997, 10:2738.
82. Devaney K.O., Travis W.D., Hoffman G., et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990, 14:555.
83. Hauer H.A., Bajema I.M., van Houwelingen H.C., et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002, 61:80.
84. Jennette J.C., Falk R.J. Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure. Med Clin North Am 1990, 74:893.
85. Weiss M.A., Crissman J.D. Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis. Hum Pathol 1984, 15:943.
86. Weiss M.A., Crissman J.D. Segmental necrotizing glomerulonephritis: diagnostic, prognostic, and therapeutic significance. Am J Kidney Dis 1985, 6:199.
87. De Remee R.A. Wegener's granulomatosis. Ann Intern Med 1992, 117:619.
88. De Remee R.A., McDonald T.J., Weiland L.H. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985, 60:27.
89. de Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461.
90. de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16:2018.
91. de Groot K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670.
92. Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomised trial of plasma exchange or high dose methyl prednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180.
93. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small vessel vasculitis. Am J Kidney Dis 2003, 42:1149.
94. Brihaye B., Aouba A., Pagnoux C., et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007, 25:S23.
95. Ferraro A.J., Day C.J., Drayson M.T., et al. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005, 20:622.
96. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262.
97. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180.
98. Jones R.B., Ferraro A.J., Chaudhry A.N., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156.
99. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126.
100. Booth A., Harper L., Hammad T., et al. Prospective study of TNFa blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717.
101. Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000, 93:433.
102. Betensley A.D., Yankaskas J.R. Factor viia for alveolar hemorrhage in microscopic polyangiitis. Am J Respir Crit Care Med 2002, 166:1291.
103. Henke D.C., Falk R.J., Gabriel D.A. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004, 140:493.
104. Ahmed S.H., Aziz T., Cochran J., et al. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage. Chest 2004, 126:305.
105. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36.
106. Metzler C., Miehle N., Manger K., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007, 46:1087.
107. WGET Investigators Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351.
108. Walsh M., Merkel P.A., Jayne D. The effect of low-dose corticosteroids on risk of relapse in ANCA-associated vasculitis: a systematic review and meta-analysis of clinical trials [abstract 2012]. 2007, American College of Rheumatology/National Scientific Meeting Highlights. Boston, November 6-11, 2007.
109. Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 1827, 68:2009.
110. Bourgarit A., Le Toumelin P., Pagnoux C., et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84:323.
111. Merkel P.A., Lo G.H., Holbrook J.T., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005, 142:620.